1. Healthcare

Instituto de
Investigaciones en Salud
Preliminary Program: VI International Symposium Helicobacter pylori: natural history
and implications for human health
Wednesday, December 3, 2014
07:30-12:00 Registration
08:00-08:30 Opening
08:30-10:00 Inaugural Lectures (Chair: Guillermo Pérez-Pérez, Francis Mégraud)
1. Dr. Pelayo Correa: Helicobacter pylori and gastric pathologies overview. Division
of Gastroenterology, Vanderbilt University Medical Center, USA.
2. Dr. Richard Peek: New insights into H. pylori-induced gastric cancer. Department
of Medicine, Department of Cancer Biology, Vanderbilt University, USA.
10:00-10:45 Coffee break
10:45-11:30 Dr. Han-Kwang Yang. Gastric Cancer Treatment in Korea. Cancer Research
Institute, Gastric Cancer Center, College of Medicine, Seoul National University, Korea.
11:30-13:30 Session 1: Epidemiology and Molecular Characterization (Chair: María
Constanza Camargo, Vanessa Ramírez)
1. Dr. María Constanza Camargo. Gastric Cancer: Opportunities for Etiologic
Research and Prevention. Division of Cancer Epidemiology and Genetics, National
Cancer Institute, National Institutes of Health, USA.
2. Dr. Catterina Ferrecio. Preliminary results of a population-based study of HP and
co-factors in two distinct areas of stomach cancer risk in Chile. Departamento de
Salud Pública, Facultad de Medicina, Pontificia Universidad Católica de Chile, Chile.
3. Dr. Douglas Morgan. Division of Gastroenterology, Vanderbilt University, USA.
Title to be announced
4. Dr. Charles Rabkin. Epidemiologic and molecular features of EBV-positive gastric
cancer. Division of Cancer Epidemiology and Genetics, National Cancer Institute,
National Institutes of Health, USA.
13:30-14:30 Lunch: posters rounds
P01: Epidemiology and Molecular Characterization
P02: Pathogenesis and Host Response
1
Instituto de
Investigaciones en Salud
14:30-15:30 Session 1(continued): Epidemiology and Molecular Characterization (Chair:
María Constanza Camargo, Vanessa Ramírez)
5. Dr. Karen Goodman. Community-driven research aimed at reducing health risks
from H. pylori infection. Division of Gastroenterology, University of Alberta,
Canada.
6. Dr. Michael Bruce. Helicobacter pylori infection in the Alaska Native population.
Arctic Investigations Program, Center for Disease Control, USA.
15:30-16:30 Session 2: Pathogenesis and Host Response. (Chair: James Fox, Warner
Alpízar)
1. Dr. James Fox. The influence of the intestinal flora on H. pylori gastric disease.
Division of Comparative Medicine; Massachusetts Institute of Technology;
Cambridge, USA.
2. Dr. Keith T. Wilson. Chemoprevention of gastric carcinogenesis by targeting
ornithine decarboxylase in high risk populations. Vanderbilt University Medical
Center, USA.
16:30-17:00 Coffee break: posters rounds
P01: Epidemiology and Molecular Characterization
P02: Pathogenesis and Host Response
17:00-18:30 Session 2 (continued): Pathogenesis and Host Response. (Chair: James Fox,
Warner Alpízar)
3. Dr. Eliette Touati. Consequences of H. pylori infection on mitochondria and their
genome. Unité de Pathogenèse de Helicobacter, Institut Pasteur, France.
4. Dr. Michael Naumann. Host response and molecular pathology in Helicobacter
infected patients. Institute of Experimental Internal Medicine, Otto von Guericke
University, Germany.
5. Dr. Céu Figueiredo. The stomach microbiota in gastric carcinogenesis. Institute of
Molecular Pathology and Immunology, University of Porto, Portugal.
18:30-20:00 Parallel workshops 1-2
W01: Epidemiology and Molecular Characterization (Chair: María Constanza
Camargo, Vanessa Ramírez)
W02: Pathogenesis and Host Response (Chair: James Fox, Warner Alpízar)
Thursday, December 4, 2014
2
Instituto de
Investigaciones en Salud
08:00-10:30 Session 3: Diagnosis and Disease Markers (Chair: Javier Torres, Clas Une)
1. Dr. Luiz Gonzaga Vaz Coelho. Contribution of 13C-urea breath test to the
knowledgement of H. pylori infection. Department of Internal Medicine, Faculty
of Medicine, Universidad Federal de Minas Gerais, Brazil.
2. Dr. Guillermo Pérez-Pérez. Characterization of the stomach microbiota by highthrough-put sequencing and the role of Helicobacter pylori. Department of
Medicine, New York University School of Medicine, USA.
3. Dr. Gunilla Høyer-Hansen. Prognostic, diagnostic and predictive value of intact
and cleaved forms of the urokinase plasminogen activator receptor in cancer.
Finsen Laboratory, Copenhagen University Hospital, Denmark.
4. Michael Ploug. Development of PET-tracer for the specific non-invasive imaging
of the urokinase receptor in cancer. Finsen Laboratory, Copenhagen University
Hospital, Denmark.
10:30-11:00 Coffee break
11:00-12:30 Parallel workshops 3-4
W03: Diagnosis and Disease Markers (Chair: Javier Torres, Clas Une)
W04: Clinical Manifestations and Treatment (Francis Mégraud)
12:30-13:45 Lunch: posters rounds
P03: Diagnosis and Disease Markers
P04: Clinical Manifestations and Treatment
13:45-16:15 Session 4: Clinical Manifestations and Treatment (Chair: Francis Mégraud)
1. Dr. Francis Mégraud. Is there one optimal treatment for a Helicobacter pylori
infection? Laboratoire de Bactériologie, Université de Bordeaux, France.
2. Dr. Tamara Matysiak. Diagnosis and management of gastric precancerous lesions.
Service d'Hépato-Gastroentérologie, Hôpital Dieu, University of Nantes, France.
3. Dr. Javier Torres. Biomarkers for the early detection of patients at risk for gastric
cancer in Latin American populations. Unidad de Investigación en Enfermedades
Infecciosas, Instituto Mexicano del Seguro Social, México.
4. Dr. Leif Andersen. Rational diagnosis of Helicobacters. Department of Infection
Control, Copenhagen University Hospital, Denmark.
5. Dr. Horacio Solano. Centro de Detección Temprana de Cáncer Gástrico, Hospital
Max Peralta, Cartago, Costa Rica. Title to be announced
16:15-16:45 Coffee break: posters rounds
P03: Diagnosis and Disease Markers
3
Instituto de
Investigaciones en Salud
P04: Clinical Manifestations and Treatment
16:45-19:00 Keynote lectures (Chair: Richard Peek, Guillermo Pérez-Pérez)
1. Dr. Martin Blaser. Complex biology of Helicobacter pylori and humans: the bad
and the good. Department of Medicine, New York University School of Medicine,
USA.
2. Dr. John Atherton. H. pylori strain determinants of gastric cancer risk…and are
any strains entirely non-pathogenic? Nottingham Digestive Diseases Centre
Biomedical Research Unit and Institute of Infection, Immunity and Inflammation
Centre for Biomolecular Sciences, University of Nottingham, United Kingdom.
3. Dr. Jean Crabtree: Extra-gastric manifestations of childhood Helicobacter pylori
infection in developing countries. Leeds Institute Molecular Medicine, St. James’s
University Hospital, University of Leeds, United Kingdom.
Friday, December 5, 2014
08:00-9:30 H. pylori and pathologies in Latin America (Chair: Pelayo Correa, Catterina
Ferrecio, Beatriz Gutiérrez, Francis Mégraud)
1. Costa Rica: Dr. Vanessa Ramírez Mayorga. Cancer Epidemiology Program, Institute
of Health Research, University of Costa Rica, Costa Rica.
2. Colombia: Dr. María Constanza Camargo. Gastric Cancer: Opportunities for
Etiologic Research and Prevention. Division of Cancer Epidemiology and Genetics,
National Cancer Institute, National Institutes of Health, USA.
3. México: Dr. Javier Torres. Unidad de Investigación en Enfermedades Infecciosas,
Instituto Mexicano del Seguro Social, México.
4. Chile: Dr. Catterina Ferrecio. Preliminary results of a population-based study of H.
pylori and co-factors in two distinct areas of stomach cancer risk in Chile.
Departamento de Salud Pública, Facultad de Medicina, Pontificia Universidad
Católica de Chile, Chile.
9:30-10:00 Coffee break
10:00-12:00 H. pylori and pathologies in Latin America (Chair: Pelayo Correa, Catterina
Ferrecio, Beatriz Gutiérrez, Francis Mégraud)
5. Latin American: Luis Carvajal. Exome sequencing of gastric tumors from Latin
American patients. Genome Center & Department of Biochemistry and Molecular
Medicine, University of California, USA.
6. Cuba: Dr. Beatriz Gutiérrez. The Need of effective preventive & therapeutic
vaccines in Latin America. Instituto de Oncología y Radiología, Cuba.
4
Instituto de
Investigaciones en Salud
7. Venezuela: Dr. María Eugenia Cavazza. Nuevas fronteras en el diagnóstico
serológico de la infección por Helicobacter pylori en Venezuela. Laboratorio de
Microbiología Molecular, Instituto de Biomedicina, Ministerio del Poder Popular
para la Salud, Universidad Central de Venezuela, Venezuela.
8. El Salvador: Dr. Douglas Morgan. Division of Gastroenterology, Vanderbilt
University, USA.
9. Honduras: Dr. Douglas Morgan. Division of Gastroenterology, Vanderbilt
University, USA.
10. Guatemala: Carmen Villagrán de Tercero. H. pylori infection and pathological
diagnosis in Guatemala. Universidad de San Carlos, Guatemala.
11. Otros países:
12:00-13:00 Lunch
13:00-15:30: CagPAI genes mini-symposium (Chair: Martin Blaser, Steffen Backert)
1. Dr. Steffen Backert: Signal transduction of the Helicobacter pylori type IV
secretion system and CagA effector protein. Department for Biology. Friedrich
Alexander University Erlangen, Germany
2. Dr. Manuel Amieva. Department of Microbiology and Immunology, Stanford
University School of Medicine, USA. Title to be announced
3. Dr. Jay V. Solnick. Functional plasticity in the type IV secretion system of
Helicobacter pylori. Center for Comparative Medicine, University of California,
USA.
4. Dr. Masanori Hatekayama. Role of Helicobacter pylori CagA oncoprotein in gastric
carcinogenesis. Division of Microbiology, Graduate School of Medicine, University
of Tokyo.
15:30-15:40 Presentation of the next meeting and closing remarks
5